Cardiovascular Systems, Inc. Announces First Patients Treated in United States with OrbusNeich Teleport® Microcatheter

Register to receive a free Interventional Cardiology Devices Market Report Suite for U.S. synopsis and brochure

Cardiovascular Systems, Inc. (CSI®), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced that the first patients in the United States were treated using the OrbusNeich® Teleport Microcatheter (Teleport), which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance.

Microcatheters are used to provide support and safe guidewire exchange during complex cardiovascular procedures. Teleport is a new generation microcatheter designed for deliverability and support, with a unique and robust tip designed to enable access in the most challenging lesions.

Annapoorna S. Kini MD, Director of the Cardiac Catheterization Laboratory at Mount Sinai Medical Center, New York, NY, and Emmanouil Brilakis, MD, PhD, FACC, FAHA, FESC, FSCAI, Interventional Cardiologist at Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, treated the first patients in the United States with Teleport.

Said Dr. Kini, “I am excited and honored to be the first to use Teleport microcatheter in the United States. Teleport allowed me to deliver the microcatheter easily through tortuous coronary vasculature while maintaining catheter position for guidewire exchange treating a complex chronic total occlusion.”

Dr. Brilakis, added, “I had the opportunity to use the Teleport Microcatheter in Europe and was impressed by its balance of deliverability and support. Teleport’s robust tip design is unique, enabling access to tight lesions while providing the torqueability necessary to treat very challenging lesions. I’m excited to have this device available to treat my patients here in the United States.”

Scott Ward, CSI’s Chairman, President and Chief Executive Officer, said, “We are committed to building a comprehensive cardiovascular company and leveraging our commercial footprint and clinical value to become the partner of choice in the revascularization of patients with complex peripheral and coronary artery disease. The clearance of the Teleport Microcatheter complements our emphasis on providing advanced solutions for the most difficult coronary and peripheral lesions.”


For Further Information

More on the interventional cardiology market in the U.S. can be found in a series of reports published by iData entitled the U.S. Market Report Suite for Interventional Cardiology Devices. This report covers the following market segments:  coronary stent, coronary balloon catheter, balloon-inflation device, interventional coronary catheter, interventional coronary guidewire, coronary embolic protection device, coronary atherectomy device, coronary thrombectomy device, chronic total occlusion system, introducer sheath, coronary vascular closure device, diagnostic coronary catheter and guidewire, intravascular ultrasound (IVUS) and optical coherence tomography (OCT).

The iData series on the market for interventional cardiology covers the U.S., Japan, and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about interventional cardiology device market data or procedure data, register online or email us at for an U.S. Market Report Suite for Interventional Cardiology Devices brochure and synopsis.

Leave a Reply